Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Equities researchers at Atb Cap Markets issued their Q1 2025 earnings estimates for Curaleaf in a research report issued to clients and investors on Tuesday, March 4th. Atb Cap Markets analyst F. Gomes forecasts that the company will post earnings of ($0.05) per share for the quarter. The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf's Q2 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.19) EPS.
Curaleaf Stock Performance
Shares of Curaleaf stock traded down $0.03 during trading hours on Friday, reaching $0.96. 556,236 shares of the stock traded hands, compared to its average volume of 744,790. Curaleaf has a one year low of $0.88 and a one year high of $6.40. The firm has a market capitalization of $634.20 million, a price-to-earnings ratio of -3.31 and a beta of 0.57. The company has a quick ratio of 0.51, a current ratio of 1.11 and a debt-to-equity ratio of 0.85. The company has a 50 day moving average price of $1.41 and a 200 day moving average price of $2.13.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.09. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%. The company had revenue of $331.05 million during the quarter, compared to analyst estimates of $331.87 million.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
